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We have used cells infected with the HIV-1 molecular clone HX10 to study the binding of monoclonal antibodies (mAbs) 
to different epitopes within the extracellular domain of the HIV-1 transmembrane glycoprotein gp41. Gp41 mAb binding to 
the infected cells at 4 ° was variable but weaker than the binding of an anti-gp120/V3 loop mAb and increased substantially 
for three of the gp41 antibodies at 37 °, Treatment of the cells with soluble CD4 (sCD4) at 37 ° increased gp41 mAb binding 
to epitopes spanning residues 521-663,  implying that these regions had probably been masked by gp120, which following 
interaction with sCD4 had subsequently dissociated from gp41. By contrast, the binding of a mAb to residues 662-667 
which form a neutralization epitope was reduced by sCD4 binding. Another region which has been described as containing 
a neutralization epitope spans residues 725-750.  MAbs to this region bound equally well to noninfected and HIV-infected 
cells, and binding was not increased in the presence of sCD4. These data strongly imply that this epitope is not exposed 
on the external surface of the membrane, a finding in accord with the proposed cytoplasmic localization of this region. 
© 1995 Academic Press, Inc. 
The env gene of the human immunodeficiency virus 
type 1 (HIV-1) codes for a single chain glycoprotein pre- 
cursor, gp160, which is cleaved to yield the mature glyco- 
proteins gp120 and gp41 (reviewed in 1). These two sub- 
units assemble into a heterodimer held together by non- 
covalent interactions and are expressed at the virion 
surface in a functional, multimeric form (2, 3). Virus bind- 
ing takes place via a high affinity interaction between 
gp120, the surface envelope glycoprotein, and the HIV 
cellular receptor, the 0D4 molecule (4, 5). Subsequent 
entry of the virion capsid into the cell takes place by 
fusion of the virus and cell membranes, an event medi- 
ated by the transmembrane glycoprotein, gp41 (6). The 
N-terminus of gp41 has been shown to contain a hy- 
drophobic fusion domain on the basis of structural ho- 
mology with the fusion domains of other enveloped vi- 
ruses (7, 8), and mutagenesis of this region leads to 
fusion-incompetent virions (9, 10). The precise mecha- 
nism by which gp41 induces virus-cell membrane fusion 
is not yet clear, but certain steps in the process are 
being elucidated. The binding of CD4 to gp120 triggers 
conformational changes in the envelope glycoproteins 
which are thought to trigger fusion in a process termed 
receptor-mediated activation of fusion (11, 12). In cell- 
line-adapted viruses the end point of these molecular 
rearrangements is dissociation of gp120 and exposure 
of gp41 (13- 16). 
Infection of 0D4 + cell lines with HIV results in a 
chronic infection in which the cell expresses no detect- 
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able CD4 but high levels of the HIV envelope glycopro- 
teins (15, 16, 23). This gp120/41 is functional as demon- 
strated by 0D4 binding and the rapid formation of syncy- 
tia in cocultures of HIV + and CD4 + cells (1). 
A number of monoelonal antibody (mAb) epitopes have 
been characterized on gp41, including two which are 
recognized by neutralizing mAbs; one in the extracellular 
membrane proximal portion (17) and one in the cyto- 
plasmic domain (18). Gp41 expressed at the surface of 
HIV-infected cells in its oligomerio, functional form was 
probed with a panel of epitope-mapped gp41 mAbs to 
determine which regions are obscured by gp120 and 
which are constitutively exposed on the surface of HIV- 
infected cells. 
The gp41 mAbs were obtained from the following 
sources: IAM 41-3E)6, IAM 41-4D4, IAM 41-2502, IAM- 
41-2F5, and IAM 41-3H 12 are human mAbs obtained from 
Viral Testing Systems (Houston, TX); 50-69 and 98-6 are 
human mAbs which preferentially recognize the oligo- 
meric form of gp41 which were prepared and epitope 
mapped as previously described (19); and 1583 and 1908 
were prepared by immunization of mice with recombinant 
chimaeric poliovirus containing the HIV gp41 sequence 
735-752 (20). The anti-gp120/V3 loop mAb 110.5 was 
obtained from Genetic Systems, Inc. (Seattle, WA), and 
the CD4 domain 4-reactive mAb L120 prepared by Bec- 
ton-Dickinson, Inc. (San Jose, CA) was obtained from 
the MRC AIDS Directed Programme, UK. 
H9 cells were infected with the HX10 clone of HIV-1 
and cultured for 8 days before use, as previously de- 
scribed (16). At this time the cells expressed no detect- 
able cell surface CD4 and high levels of the HIV envelope 
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glycoproteins as determined by immunofluorescent 
staining with the anti-gp120 mAb 110.5. One million cells 
in a volume of 100 #1 were incubated for 2 hr with or 
without soluble CD4 (sCD4 from R. Sweet, Smith, Kline 
and Beecham, King of Prussia, PA; 21) at 10 ffg/ml at 4 
or 37 ° with agitation, washed, and then stained with the 
anti-gp41 mAbs for 1 hr at 4 or 37 ° with agitation before 
washing and fixation overnight in 2% formaldehyde. After 
further washing an appropriate dilution of anti-human 
immunoglobulin coupled to phycoerythrin (Immunotech 
SA, Luminy Case 915, Marseille, France)was incubated 
with the fixed cells for 1 hr at 4 ° with agitation followed 
by washing as before. Flow cytometric analysis was car- 
ried out using a Becton-Dickinson FAOScan with Con- 
sort 30 software. 
The interaction of sOD4 with gp120 of cell-line-adapted 
HIV-1 isolates at 37 ° induces the dissociation of gp120 
from gp41 (13-16). In order to determine which regions 
of gp41 are masked by gp120 and which are constitu- 
tively exposed, a panel of gp41 mAbs with known epi- 
topes was used to stain uninfected or HIV-infected, env- 
expressing H9 cells in the presence or absence of pre- 
bound sCD4. The background staining with uninfected 
cells was subtracted from the specific signal obtained 
with the infected cells. 
In the absence of sOD4, staining of HIV-infected H9 
cells with the gp41 mAbs at 4 ° was variable but relatively 
weak by comparison with the signal obtained with the 
gp120 mAb 110.5 (Fig. 1). This low-level gp41 staining is 
in accord withprevious tudies (15, 16, 22, 23) and proba- 
bly reflects the constitutive partial exposure of gp41 mol- 
ecules in the presence of gp120, but may also imply 
the exposure of a small proportion of gp41 molecules 
resulting from a basal level of spontaneous gp120 disso- 
ciation. 
Following the addition of sOD4 at 4 ° , staining in- 
creased subtly for all mAbs except the neutralizing mAb 
2F5 (Fig. 1). This small increase in mAb reactivity is prob- 
ably the result of low-level gp120 dissociation which oc- 
curs with some isolates of HIV-1 in the presence of sCD4 
at 4 ° (16). The binding of sCD4 to the cells was verified 
by staining with the anti-CD4 mAb L120; gp120 binding 
does not interfere with L120 since this mAb reacts with 
domain 4 of 0D4 (15). Incubation of the cells with sOD4 
at 37 ° resulted in a diminution of cell surface gp120-0134 
complexes as demonstrated bythe decreased binding of 
the 110.5 and L120 mAbs. The reduction in cell-surface 
gp120 induced by sOD4 was estimated from the de- 
crease in sOD4 staining using mAb L120 (calculated by 
dividing the value obtained at 4 ° with that obtained at 
37 ° ) and the decrease in gp120 staining using mAb 110.5 
(calculated by dividing the value obtained with untreated 
ceils by that obtained with ceils treated with sCD4 at 
37 °) and was 2.3- and 2.8-fold, respectively (mean of two 
separate experiments). By this analysis the decrease in 
110.5 staining was consistently greater than the de- 
crease in sCD4 staining, probably resulting from a small 
reduction in signal obtained with sCD4 treatment at 4 ° 
as a result of low-level shedding. 
The binding of all gp41 mAbs with the exception of 
2F5 was increased substantially after sOD4 pretreatment 
at 37°; 2502, 50-69, 3D6, and 98-6 showed maximum 
increases (mean of two separate experiments) over 
sOD4-untreated cells of 6.4-, 2.8-, 2.7-, and 5.8-fold, re- 
spectively. The greater reactivity of these mAbs following 
sCD4 treatment at 37 ° is very likely to be a direct result 
of gp120 dissociation revealing previously occluded por- 
tions of gp41, since it has been shown previously that 
the increase in gp41 staining correlates with the level of 
gp120 dissociation (16). The variation between mAbs in 
the level of binding enhancement probably reflects the 
ratio of preexposed to sOD4-induced exposure of gp41 
epitopes; 50-69 and 3D6 bind gp41 relatively well in the 
absence of sOD4-induced gp120 dissociation, whereas 
2502 and 98-6 bind poorly. 
Since the gp41 mAbs interact with HIV virions in vivo 
at physiological temperature, we decided to test the bind- 
ing of the gp41 mAbs to the infected cells at 37 ° (Fig. 2). 
The signal obtained at 37 ° with the mAbs 2502, 50-69, 
3D6, 98-6, and 2F5 increased by 1.6-, 0.9-, 1.0-, 4.3-, and 
10.6-fold, respectively (mean of two experiments) over 
that observed at 4 ° . Thus, raising the temperature in- 
duced a dramatic increase in the exposure of the two 
membrane proximal epitopes (644-663 and 662-667) 
and a modest increase in the NH2-terminal epitope (521 - 
538). In the presence of sCD4 prebound at 37 °, mAb 
reactivity at 37 ° was 1.8-, 0.9-, 1.1-, 3.4-, and 6.9-fold 
greater than that at 4 ° for mAbs 2502, 50-69, 3D6, 98-6, 
and 2F5, respectively, implying that increasing the tem- 
perature for the mAb binding step did not substantially 
alter the level of sOD4-induced gp120 dissociation. 
Surprisingly, sCD4 binding induced a decrease in 2F5 
binding which was detectable at 4 ° (1.3-fold, mean of two 
experiments) and became more obvious at 37 ° (2.1-fold, 
mean of two experiments). Thus unlike the other gp41 
mAbs tested, the 2F5 epitope is constitutively strongly 
exposed on the surface of infected cells at 37 °, and mAb 
reactivity is reduced in the presence of sCD4. The tem- 
perature dependence of this epitope may relate to its 
availability within the gp41 oligomer; at 4 ° the epitope 
may be obscured by gp120, by carbohydrate groups, by 
another gp41 molecule, or by other membrane compo- 
nents. Increasing the temperature may allow the oligo- 
meric structure to "relax" somewhat within the mem- 
brane, thereby freeing the epitope. The sCD4-induced 
reduction in 2F5 signal is more difficult to explain, but 
may result from a conformational modification of the epi- 
tope induced indirectly by sCD4 binding to gp120, directly 
via an interaction between sOD4 and gp41, or from epi- 
tope masking caused by a receptor binding-induced in- 
teraction of gp41 with other molecules in the infected 
cell or virion membrane. Binding of the 2F5 mAb to gp41 
may inhibit HIV fusion by interfering with one the above- . 
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FIG. 1. Effect of sCD4 on gp41 mAb binding. The gp41 mAbs were incubated at the concentrations hown with HIV-l-infected H9 cells which 
had been pretreated or not with sCD4 at 4 or 37 °, followed by an anti-human immunoglobulin-phycoerythrin-coupled second antibody. MAb binding 
was analyzed by flow cytometry using a FACScan with Consort 30 software. Each datum point represents the mean fluorescence intensity of 10,000 
accumulated eveners, from which the signal obtained with uninfected cells has been subtracted= mAb binding in the absence of sCD4 is represented 
by (O), in the presence of sCD4 at 37 ° (Iq), and at 4 ° (A). Note that the vertical scale (mean fluorescence intensity) for 2502, 50-69, and 3D6 differs 
from that of 98~6 and 2F5. The epitope position for each mAb is presented in parentheses after the mAb names and is numbered according to the 
BH10 amino-acid sequence; minimum epitopes for 50-69 and 98-6 were taken from Xu et al. (19), 2F6 from Muster et al. (123, and 2502 and 3D6 
from the commercial literature accompanying these mAbs. The boxed histogram shows staining by mAbs 110.5 (gp120 V3 loop) and L120 (0D4 
domain 4) at 10 #g/ml of cells from the same experiment described above carried out under the same conditions. Open (El) bars represent mAb 
staining of untreated, HIV-infected H9 cells; hatched ([]) bars represent staining of infected cells pretreated with sOD4 at 4°; and filled (B) bars 
represent staining of infected cells pretreated with sCD4 at 37 °. 
mentioned pathways or may function by yet another un- 
known mechanism. 
Figure 3 illustrates graphical ly the location of the epi- 
topes which, from the results presented in this study, are 
exposed in the presence of gp120, and those which are 
likely to be completely or partially occluded. It is clear 
that the majority of the extracellular portion of gp41, at 
least that comprising residues 521-663, is likely to be 
partially or completely masked in the presence of gpl  20. 
This is in good agreement with tlhe widely spaced diver- 
sity of mutations indicated in Fig. 3 which disrupt the 
gp120/CD4 interaction. The only mAb epitope which ap- 
pears well exposed in the presence of gp120 is that of 
2F5 which is the most membrane proximal (662-667), 
although mAb binding is highly temperature dependent. 
The cytoplasmic domain of gp41 has been reported to 
contain a neutralizing epitope spanning residues 735-  
752 (18, 20). MAbs have been prepared in mice against 
recombinant polioviruses containing this region of HIV 
gp41, which neutralize in a relatively type-specific man- 
ner (24). We have tested two of these reagents and a 
human mAb with similar epitope specificity for binding 
to cell surface-expressed gp41 in the presence or ab- 
sence of sOD4. Figure 4 compares the binding of four 
mAbs to uninfected H9 cells and sOD4 pretreated or 
untreated HX10-infected H9. The gp120 mAb 110.5 gave 
a strong signal, and pretreatment of the cells with sOD4 
reduced the signal by about threefold. MAb 98-6 to the 
extracellular domain of gp41 reacted weakly with in- 
fected H9 cells in the absence of sOD4 and substantially 
more strongly in the presence of sCD4 preadsorbed to 
the cells at 37 ° . Two neutralizing anti-HIV (735-752) 
mAbs, 1583 and 1908 (20, 24), gave intermediate binding 
to H9 and gave an identical signal on infected H9 cells. 
Treatment with sOD4 resulted in a small diminution in 
staining in this experiment, but this was not a reproduc- 
ible finding. Similar results were obtained for 3H12, a 
human mAb reactive with an epitope within the gp41 
sequence 693-856 (data not shown). These three mAbs 
were demonstrated to be active in a peptide ELISA; all 
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FIG. 2. Temperature dependence of gp41 mAb binding. HW-infected 
H9 cells either untreated ( i )  or preincubated with sCD4 (10 #g/ml) for 
1 hr at 37 ° ([~) were washed and incubated for 2 hr with the mAbs 
shown at 37 ° (A) or 4 ° (B). After overnight fixation the cells were stained 
with anti-human conjugated phycoerythrin and analyzed by flow cytom- 
etry as described in the legend to Fig. 1. The histogram bars represent 
the mean fluorescence intensity obtained from the analysis of 10,000 
accumulated events from which the signal obtained with uninfected 
H9 cells has been subtracted. 
in HIV infection. (1) The immunodominant disulfide-linked 
loop and flanking regions which have been suggested 
to form a conserved structural motif which functions in 
the association of the surface and transmembrane glyco- 
proteins of lentiviruses (26). Moreover, peptides synthe- 
sized from the sequence of this region bind to cellular 
proteins of 45 and 80 kDa, an association which has 
been suggested to represent a potential HIV-coreceptor 
interaction (27). (2) A predicted o~-helical region spanning 
residues 558-595, structural conservation of which is 
importantfor infectivity, and peptides from which inhibit 
HIV-mediated fusion (28). Antiserum raised against this 
peptide binds better to HIV-infected cells in the presence 
of sCD4, a finding which concurs with our suggestion 
that this region is at least partially masked by gp120. (29). 
)-69 
3DE 
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gave strong signals with the peptide 735-752, but no 
significant activity with an irrelevant peptide (data not 
shown). It thus appears that the gp41-specific epitope(s) 
for these mAbs is not expressed at the surface of HIV- 
infected cells. This is in accord with the predicted intra- 
cellular location of the cytoplasmic tail of gp41, there 
being no evidence for a second transmembrane span- 
ning region. These findings differ from results presented 
in another study (25), in which HIV-infected cells reacted 
more strongly than uninfected cells with an anti-735-752 
peptide mAb. The reason for this discrepancy is unclear, 
and the mechanism of neutralization of HIV by these 
mAbs remains obscure. 
The HIV-cell fusion process is thought to be mediated 
by a direct interaction between the hydrophobic N-termi- 
nal fusion domain of gp41 and the cell membrane (1). 
Our current thinking suggests that this region is probably 
masked by gp120 until the virus and cell membranes are 
in close apposition, when a process termed receptor- 
mediated activation of fusion triggers the exposure of the 
fusion domain (11, 12). In addition to the fusion domain, 
there are other regions which are potentially functional 
carboxy 
terminus ,~. JD %®®- 
Extracellular 
Intracellular 
FIG. 3. Regions of gp41 masked by gp120. The amino-acid backbone 
and proposed secondary structure are modified from Gallaher et al. 
(33). The thick black line represents the regions of gp41 which are 
likely to be partially or completely masked by gp120 in the functional 
giycoprotein oligomer. It is unclear from this study whether the N- 
terminal portion of the fusion peptide is masked by gp120, since the 
epitope of mAb 2502 is reported to begin at residue 521, and no 
reagents specific for the region N-terminal to this have been tested. The 
arrowheads, some of which are numbered according to the published 
sequence of HIV-1 BH10, indicate residues which are thought to be 
critical for gp120 association (taken from Cao et aL, 30). The epitope 
for each of the mAbs tested is boxed and labeled, and the epitope for 
mAb 2F5 (662-667) is shaded. 
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FIG. 4. Staining of HIV-infected and uninfected cells by mAbs to gp41 
cytoplasmic domain. HIV-l-infected H9 cells either pretreated (---) or 
not (. • .) with sCD4 and uninfected H9 cells (. • .) were incubated 
fluoreehrome conjugated second antibody alone ( - - )  or with the 
. . . .  1 antibodies shown at a d dut~on of either ~-~ for ascites or a concentration 
of 30 fig/el for purified immunoglobulin for 2 hr at 4 ° with agitation, 
washed, and then fixed. After a further wash the cells were labeled 
with phycoerythrin-coupled second antibodies and then analyzed by 
flow cytometry on a FAOScan using Consort 30 software. Each peak 
represents the accumulation of 10,000 gated events. Note that the 
staining of uninfected and HIV-infected cells with mAbs 1583 and 1908 
is superimposed in this experiment. 
(3) The coflserved neutralization epitope located close to 
the membrane on the extracellular segment of gp41 (17). 
The data presented here imply that gp41 and gp120 inter- 
act over a large surface, a conclusion which is not sur- 
prising considering the variety of mutations in both sub- 
units which interfere with this interaction (6, 30-32,  Fig. 
3). Further studies using viral glycoproteins expressed 
in a functional form at the cell surface may be useful for 
the dissection of other structure-function relationships. 
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